Idorsia | Portfolio overview

Bench to bedside

Bench to bedside

Learn all about our strategic priorities to enable delivery on our ambitious goals.
Portfolio
Portfolio

Idorsia aims to deliver new products with the potential to significantly change the treatment options in their target diseases. We want to bring new perspectives to the discovery, development, and commercialization of innovative treatments, challenging accepted paradigms to answer the questions that matter most.
Target Diseases
Target Diseases

Our drug discovery approach has led to a pipeline of compounds that are active in many different therapeutic areas. Learn more about the diseases that we are targeting.
Serving patients

Serving patients

Idorsia-led Portfolio

The company will develop each asset to the next inflection point or seek a partner.

Compound	Mechanism of action	Target indication	Status	More Information
QUVIVIQ™ (daridorexant)	Dual orexin receptor antagonist	Insomnia	Commercially available in the US, Germany, Italy, Switzerland, Spain, the UK, Canada, Austria, France, and Sweden; approved throughout the EU	Investor webcast
Lucerastat	Glucosylceramide synthase inhibitor	Fabry disease	Phase 3 open-label extension study ongoing – kidney biopsy sub-study results expected in Q2 2025 – regulatory pathway to be further discussed with FDA
Daridorexant	Dual orexin receptor antagonist	Pediatric insomnia	Phase 2 in pediatric insomnia ongoing
ACT-777991	CXCR3 antagonist	Vitiligo	Proof-of-concept study in preparation
ACT-1004-1239	ACKR3 (CXCR7) receptor antagonist	Progressive multiple sclerosis	Proof-of-concept study in preparation
IDOR-1117-2520	CCR6 receptor antagonist	Psoriasis	Proof-of-concept study in preparation
ACT-1016-0707	LPA 1 receptor antagonist	Immune-mediated and fibrosis related disorders	Entry-into-human package complete
IDOR-1134-9712	CFTR Type-IV corrector	Cystic Fibrosis	Entry-into-human package in progress
IDOR-1126-6421	Undisclosed mechanism	Organ injury / fibrosis	Entry-into-human package in progress
IDOR-1141-8472	Orexin 2 receptor agonist	Orexin-related CNS disorders	Entry-into-human package ready to begin

Synthetic Glycan Vaccine Platform			Idorsia will seek a partner for the platform or individual vaccines
IDOR-1134-2831	Synthetic glycan vaccine	Clostridium difficile infection	Idorsia is conducting a Phase 1 clinical pharmacology study – Results expected in Q2 2025.
IDOR-1142-0810	Synthetic glycan vaccine	Klebsiella pneumonia infection	Entry-into-human package in progress.

Partner-led Portfolio

Compound	Mechanism of action	Target indication	Partner: Terms	Status
TRYVIO™ (aprocitentan)	Dual endothelin receptor antagonist	Systemic hypertension in combination with other antihypertensives	To be defined: worldwide development and commercialization rights	Commercially available in the US
JERAYGO™ (aprocitentan)	Dual endothelin receptor antagonist	Resistant hypertension in combination with other antihypertensives	To be defined: worldwide development and commercialization rights	Approved in the EU and UK; Marketing authorization applications submitted in Canada, and Switzerland
QUVIVIQ™ (daridorexant)	Dual orexin receptor antagonist	Insomnia	Nxera Pharma: license to develop and commercialize for Asia-Pacific region (excluding China)	Launched for the treatment of insomnia in Japan; Phase 3 ongoing in South Korea
Daridorexant	Dual orexin receptor antagonist	Insomnia	Simcere: license to develop and commercialize for the Greater China region	Approved for the treatment of insomnia in Hong-Kong
Selatogrel	P2Y₁₂ inhibitor	Suspected acute myocardial infarction	Viatris: worldwide development and commercialization rights	Phase 3 “SOS-AMI” program ongoing
Cenerimod	S1P₁ receptor modulator	Systemic lupus erythematosus	Viatris: worldwide development and commercialization rights	Phase 3 “OPUS” program ongoing
Daridorexant	Dual orexin receptor antagonist	Posttraumatic stress disorder (PTSD)	US Department of Defense (DOD): Idorsia supports a clinical study sponsored by the US DOD to develop new therapies to treat PTSD	Phase 2
ACT-1002-4391	EP₂ / EP₄ receptor antagonist	Immuno-oncology	Owkin: global license to develop and commercialize	Phase 1 ongoing